PSA Peugeot Citroen and Delphi Sign Development Contract
2 October 2000
PSA Peugeot Citroen and Delphi Sign Development Contract On Non-Thermal Plasma Exhaust AftertreatmentPARIS, Sept. 29 At the Mondial de l'Automobile here, PSA Peugeot Citroen and Delphi Automotive Systems announced they have signed an innovation agreement to apply non-thermal plasma exhaust aftertreatment (NTP) to future Peugeot Citroen vehicles. The agreement commits PSA Peugeot Citroen and Delphi to developments of technology for future vehicle applications. NTP, which was developed by Delphi, reduces oxides of nitrogen (NOx) and particulate emissions in direct injection gasoline and diesel engines. NTP devices produce high energetic electrons that collide with the background gas molecules, producing radicals that promote selective partial oxidation of NO to NO2. The NO2 generated through the NTP is reduced by an appropriate catalyst technology to non-harmful gasses. In addition, this NO2 also enables a continuous regeneration of particulate filter, which eliminates particulate matter, even the smallest ones. In steady-state testing of a diesel vehicle, the non-thermal plasma exhaust aftertreatment system has demonstrated greater than 65 percent reduction of oxides of nitrogen emissions without additional hydrocarbons to the exhaust stream, greater than 85 percent with additional hydrocarbons, as well as demonstrating a significant reduction in particulates. Delphi has focused on a breakthrough reactor design that is durable, compact and energy efficient. This partnership will continue to develop NTP as a solution to allow future Peugeot Citroen vehicles to satisfy Euro4 regulations beginning Jan. 1, 2005. "Last year Delphi's NTP was recognized at the Financial Times Global Automotive Awards ceremony in Frankfurt, Germany," said Guy C. Hachey, president of Delphi Energy & Chassis Systems. "I am very pleased to be at this year's Paris Mondial to announce the next advancement of this technology through this important development agreement with PSA."